PD-L1 expression and tumour mutation burden (TMB) remain the most applied biomarkers for predicting immunotherapy response [173], with NSCLC patients showing high PD-L1 expression typically obtaining better benefits from anti-PD-1/PD-L1 therapy [174]. This evidence concerns the gene CD274 and neoplasm.